This company listing is no longer active
0CB Stock Overview
A pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oxford Cannabinoid Technologies Holdings Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.001 |
| 52 Week High | UK£0.01 |
| 52 Week Low | UK£0.001 |
| Beta | 0.60 |
| 11 Month Change | 0% |
| 3 Month Change | -80.00% |
| 1 Year Change | -90.91% |
| 33 Year Change | -98.18% |
| 5 Year Change | n/a |
| Change since IPO | -98.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0CB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.02% |
| 1Y | -90.9% | -20.1% | 8.2% |
Return vs Industry: 0CB underperformed the German Pharmaceuticals industry which returned -17.6% over the past year.
Return vs Market: 0CB underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| 0CB volatility | |
|---|---|
| 0CB Average Weekly Movement | 22.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0CB's share price has been volatile over the past 3 months.
Volatility Over Time: 0CB's weekly volatility has decreased from 50% to 22% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 7 | Clarissa Sowemimo-Coker | www.oxcantech.com |
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase – I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia.
Oxford Cannabinoid Technologies Holdings Plc Fundamentals Summary
| 0CB fundamental statistics | |
|---|---|
| Market cap | €1.47m |
| Earnings (TTM) | -€4.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs 0CB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0CB income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£2.33m |
| Gross Profit | -UK£2.33m |
| Other Expenses | UK£1.91m |
| Earnings | -UK£4.24m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0039 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0CB perform over the long term?
See historical performance and comparison